drugset
Drugs / AQ-13
last change Feb 2017 re-read 9 days ago

AQ-13

Small molecule

Developed for
Plasmodium falciparum malaria
Investigated by
Tulane University Health Sciences Center · Centers for Disease Control and Prevention · National Institute of Allergy and Infectious Diseases (NIAID) · Tulane University · University of the Sciences, Techniques and Technologies of Bamako

Trials 3

today NCT01614964 · Ph 2 NCT00455494 · Ph 1 NCT00323375 · Ph 1
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT00455494 Jan 2005 → Dec 2006 malaria Tulane University Health Sciences Center Completed No outcome recorded
Phase 1 NCT00323375 Aug 1999 → Jun 2005 malaria Tulane University Health Sciences Center Completed No outcome recorded
Phase 21 trial · 1 missed
Phase 2 NCT01614964 Aug 2013 → Jan 2016 Plasmodium falciparum malaria Tulane University Completed Missed primary

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as AQ-13 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00323375 ↗
2

NCT01614964 ↗

NCT00455494 ↗
Modality Small molecule “investigational aminoquinoline antimalarial (AQ-13)” NCT00323375 ↗
Route Oral “administered orally” NCT00323375 ↗